Comparison of Patient Tolerance of Photodynamic Therapy with Zone vs. Full Face Treatment by Aleshaki, Joseph, OMS-II & Crawford, Dr. Kevin
MUShare
Scholarship, History, Art, Research, and Engagement
MU-COM Research Day College of Osteopathic Medicine
2015
Comparison of Patient Tolerance of Photodynamic
Therapy with Zone vs. Full Face Treatment
Joseph Aleshaki OMS-II
Marian University - Indianapolis, jaleshaki093@marian.edu
Dr. Kevin Crawford
Marian University - Indianapolis
Follow this and additional works at: http://mushare.marian.edu/mucom_rd
Part of the Chemicals and Drugs Commons, Dermatology Commons, and the Neoplasms
Commons
This Poster is brought to you for free and open access by the College of Osteopathic Medicine at MUShare. It has been accepted for inclusion in MU-
COM Research Day by an authorized administrator of MUShare. For more information, please contact emandity@marian.edu.
Recommended Citation
Aleshaki, Joseph OMS-II and Crawford, Dr. Kevin, "Comparison of Patient Tolerance of Photodynamic Therapy with Zone vs. Full
Face Treatment" (2015). MU-COM Research Day. 8.
http://mushare.marian.edu/mucom_rd/8
www.postersession.com
Photodynamic Therapy (PDT) is a promising treatment 
option for actinic keratosis, superficial basal cell 
carcinoma, and in-situ squamous cell carcinoma.
The fundamental basis of PDT lies in the selective 
destruction of target tissue photochemical reaction 
when light is absorbed by a photosensitizing agent 
applied on the affected skin surface. In an effort to 
increase patient compliance, dermatologists 
systematically apply photosensitizing agents to smaller, 
defined treatment areas.
We hypothesize that development of standardized 
treatment zones for photodynamic therapy would result 
in improved patient comfort, higher patient retention, 
and less severe reactions while maintaining the efficacy 
of full face treatments.
Methods Conclusions
Comparison of patient tolerance of photodynamic therapy with 
zone vs. full face treatment
Kevin M. Crawford, Joseph S. Aleshaki
Indiana University Department of Dermatology, Marian University College of Osteopathic Medicine
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Zone treatment resulted in a higher number of excellent 
responses for patient tolerance vs. full face treatment 
group (85 % vs. 39%, P<0.0001).
More patients would undergo follow up zone treatments 
versus full face treatment (96% vs. 77.9%, P <0.0001).
There were fewer severe reactions in the zone treatment 
group (n = 3 vs. n = 34, P <0.0001).
Zone treatments displayed higher patient retention 
(92.8% vs. 68.0%, P<0.0001).
Table 1 – Patient Tolerance
Table 2 – Would Patient Repeat Treatment
Table 3 – Complications/Severe Reactions
Table 4 – Patient Retention
Our study found that zone therapy patients experienced 
increased comfort, satisfaction, and retention with fewer 
complications as compared to full face treatment. 
A limitation of this study includes that it has been 
performed at a single, rural clinic in Southern Indiana. 
Geographic, climate and other differences must be 
considered before assuming that these results are able 
to be generalized to other patient populations.
While patient tolerance is improved with zone therapy, 
the increase in cost of the procedure should not be 
ignored.
Levulan Kerasticks currently cost approximately $160. 
Therefore, reagent cost alone for zone therapy is $960 
vs. $320 for full face treatment. Additionally, the 
Medicare reimbursement for PDT treatment itself is 
approximately $125. Thus, zone treatment accrues a 
cost of $750 vs. $250 for full face treatments.
Each dermatologist should pose the question whether 
the benefits of increased patient tolerance, comfort, and 
retention outweigh the obvious increase in cost of the 
regimen.  6 Zone treatments also require several weeks 
more time to complete than 2 full face treatments. 
Introduction Results
Five hundred patients with 12 or more actinic keratosis 
were selected for the study. Patients were divided into 
full face (n=250) vs. zone treatments (n=250) for their 
PDT treatments. Treatments were separated by 3-4 
weeks. Full face was defined as the entire forehead, 
nose, bilateral cheeks, entire chin, and bilateral ears.
Patients were prepped with acetone and 20% 
aminolevulanic acid solution (Levulan) and incubated 
for 60 minutes. They were exposed to narrow band 
blue fluorescence for 16 minutes and 40 seconds. 
After 48-72 hours post-treatment, patients were asked 
the following questions:
1. Grade their tolerance of the treatment regimen as 
Excellent, Fair, or Poor
2. Would you have the treatment again 
(Yes/No/Unsure)
For the Zone Treatment Group, Zones were defined as:
1. Zone A: Forehead, nose
2. Zone B: Left ear, left cheek, left chin
3. Zone C: Right ear, right cheek, right chin
Excellent Fair Poor Not able to contact
Zone Treatment: 193 (84.6%) 19 (8.3%) 14(6.14%) 24
Full face treatment: 90 (39.0%) 76 (32.9%) 65 (28.1%) 19
P-value: <0.0001 <0.0001 <0.0001
Yes No Unsure
Zone Treatment 96.0% (217/226) 2.2% (5) 1.8% (4)
Full Face Treatment 77.9% (180/231) 17.3% (40) 4.8% (11)
P-value <0.0001
Number of patients 
Zone Treatment n=3   (1.2%)
Full Face Treatment n=34 (13.6%)
P-value <0.0001
Retention Percentage
Zone Treatment 92.8%  (232/250)
Full Face 68.0%  (170/250)
P-value <0.0001
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